Related diseases

Overview

Image found on runkle-science.wikispaces.com.

Hemochromatosis is an autosomal recessive disorder responsible for an abnormal iron overload in blood. As a consequence, the organism starts to stock the iron in many tissues and organs like the heart, the liver and the pancreas. This accumulation of iron leads to cellular damage as well as chronic insufficiencies. Hemochromatosis affects 2 200 000 persons in Europe and 2 000 000 in the US.

Pathophysiology & Genetics

There are different types of hemochromatosis but the most common is the type I which represents 95% of the cases. This type of hemochromatosis is due to homozygous mutations in the High Fe Gene (HFE) like the C282Y or the H63D mutations.

HFE gene normally encodes a protein which interacts and forms a complex with other proteins on cells surface in order to sense the iron concentration in the organism. In doing so, the HFE protein then activates the production of a peptide hormone called hepcidin when needed. The hepcidin, which is a key iron regulatory hormone, inhibits the dietary iron assimilation occuring in the duodenum by inducing the degradation of the iron exporter - the ferroportin. In the end, the interaction between the HFE protein and hepcidin allows a tight regulation of the iron homeostasis by the organism.

In case of type I hemochromatosis, the HFE protein is altered and cannot upregulate hepcidin levels. As a consequence, the body keeps absorbing massive amounts of iron. Indeed, a patient suffering from hemochromatosis assimilates everyday four times more iron than normal: 5-8 mg instead of the usual 1-2 mg.

Consequences

As explained, iron gradually accumulates in the organism of patients with hemochromatosis, unoticed, until clinical signs like chronic fatigue and joint pain appear around 35-40 years old. Because of this type of early symptomps, hemochromatosis is often misdiagnosed but if left untreated, it can causes many life-threatening conditions like heart failure, diabetes or liver cancer.

Treatment

Image found on aboutphlebotomytraining.com/.

Nowadays, the only way to treat hemochromatosis is by therapeutic blood removal, also known as phlebotomy. Up to 500 mL of blood can be removed and a person with severe iron overload may have to give blood eight times a month. Although effective, this treatment is invasive and has major impacts on a patient’s life. Indeed, some people hardly tolerate it and suffer from it as it causes huge fatigues. What is more, regular phlebotomies are time consuming and complicate the professional and private life of patients.

That is why we wanted to create our Iron Coli as it would allow patients to live a more regular life style, significantly decreasing the frequency of blood removal needed. Our project would represent an innovative and life-changing alternative treatment for person with hemochromatosis.

Overview

Thalassemias are inherited autosomal recessive disorders frequently encountered around the mediterranean sea. They are due to mutations in genes coding hemoglobin monomers causing malformations and destruction of red blood cells, which lead to mild or severe anemia. People with thalassemia also suffers from an iron overload that is ironically caused by the treatments used to cure anemia. It has been estimated that 100 000 children per year in the world are diagnosed with a severe form of thalassemia.

Pathophysiology & Genetics

Image found on www.mdkiosk.com/.

Thalassemia affects the hemoglobin, an iron rich protein found in red blood cells, which transports the oxygen through the entire body. Its role is therefore crucial.

Hemoglobin is normally composed of four protein chains - two alpha and two beta globins - which are respectively coded by four and two genes. Thalassemia trait occurs when at least one of those genes are mutated and depending on which chain/globin is altered, we distinguish two main types of thalassemia named alpha and beta thalassemias. Severity of the disorder is actually determined by the number of mutated genes.

In all cases, thalassemia is characterized by an imbalanced production of the alpha and beta globins which leads to a very low number of hemoglobin formed. Furthermore, accumulation in red blood cells of the chains that are in higher copy, results in an abnormal and excessive destruction of red blood cells causing anemia.

Consequences

Symptoms of thalassemia include bone deformities, fatigue as well as growth failure. Thalassemia can also give rise to many other complications because of the lack of effective red cells in the oxygen transport mechanism. Indeed, it results in a fake signal of low iron centration in blood, thus inducing an iron over absorption from the duodenum in a similar way of hemochromatosis. Heart and liver diseases due to iron overload remain the major cause of death in people suffering from thalassemia disorder.

Treatment

Our Iron Coli: a possible innovative and life-changing new medicine !

Nowadays, several remedies exist to cure thalassemia. For severe cases, a bone marrow transplant is possible. Otherwise, treatments often involves blood transfusions in order to restore a sufficient level of healthy red blood cells with normal hemoglobin. Depending on the severity of thalassemia, blood transfusions may last 10 - 12 hours with a frequency of 2 to 4 times a week! Even though effective, this treatment has the major inconvenience of being so much time consuming and expensive.

What is more, the regularity of blood transfusion leads to a massive increase of the amount of iron in blood, which adds to the already existing iron overload caused by the disease itself. Therefore, patients have to follow a supplementary iron chelation therapy based on iron chelators like Deferasirox. Again, this therapy involves major side effects (headache, vomiting, diarrhea, fatigue etc…) but it is sadly necessary as phlebotomy is prohibited because people suffering from thalassaemia are anemic !

Finally, treating thalassemia remains nowadays very complicated and hard on patients’ lifes. That is why our Iron Coli would represent a huge hope for patients with thalassemia as it would replace current chemical iron chelators, making their treatments much more bearable.